Diluted HEPS of 453.9cps (FY24: 73.2cps). The net positive extraneous contributions to Group earnings for FY25 were all attributable to the Group’s investment in Cell C.
Revenue decreased by 3.8% y-y to R14 050m.
Operating margin up by 270bps to 10.0%.
Operating expenses decreased by 6.7% y-y, with operating expense to revenue of 90.5% (FY24: 93.4%).
No dividend (FY24: nil).
Cashflow from operations down by 55.2% y-y to -R466m.
Gross debt increased from R4.1bn to R5.5bn, while net cash decreased from R896m to R821m. Net debt to EBITDA increased from 2.59x to 2.89x.
